A Registry for Patients Taking Uptravi

Inclusion Criteria:

• Signed patient informed consent form (ICF).

• Patients ≥ 18 years of age at time of Uptravi initiation, and

• Patients who initiate Uptravi:

• at enrollment, or

• less than or equal to 60 days prior to enrollment and have a documentedtitration regimen (defined as all documented dose changes including, but notlimited to: starting dose and dates and highest tolerated dose and dates)

Exclusion Criteria:

• Patients previously exposed to Uptravi treatment during a clinical trial.

• Patients that previously discontinued Uptravi for any reason, prior to studyenrollment (discontinuation defined as an interruption of therapy greater than orequal to 30 days).

• Patients enrolled in a blinded clinical trial or in a clinical trial involving anunapproved drug.